Medicus Pharma submits development plan for novel Equine Cancer treatment

Описание: Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce the submission of a comprehensive product development plan to the U.S. FDA for the treatment of external squamous cell carcinoma (SCC) in horses. The submission was made under the Investigational New Animal Drug (INAD) program and seeks concurrence under the Minor Use in Major Species (MUMS) designation.

The FDA recently granted MUMS designation to Medicus Pharma’s dissolvable Doxorubicin-containing microneedle array, which is specifically designed to treat external SCC in equine patients. This recognition enables the company to pursue regulatory pathways designed to support treatments for rare conditions in major animal species.

Dr. Bokhari explained that SCC is a skin tumor commonly affecting adult or aging horses with white or partially white coats. Breeds such as Appaloosa, Belgian, American Paint, and Pinto are particularly vulnerable. The incidence of SCC in horses is estimated at 2-3%, with the U.S. horse population currently ranging from 6.6 to 7.25 million animals.

Current treatment options involve surgical removal of larger tumors, cryotherapy for smaller lesions, and localized or topical chemotherapy. Some cases are also managed with oral medications like piroxicam to slow cancer recurrence. Bokhari noted that the company’s microneedle platform could offer a less invasive and more targeted treatment alternative.

With the development plan now submitted, Medicus Pharma is aiming to align with the FDA on next steps to bring this innovative treatment to market, providing a new option for veterinarians and horse owners dealing with equine SCC.

#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation VeterinaryOncology #HorseCancer #SquamousCellCarcinoma #FDAApproval #AnimalHealth